Supplemental material
Research Articles
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial
David Adamsa Neurology Department, CHU Bicêtre, APHP, Université Paris-Saclay, Le Kremlin Bicêtre Cedex, FranceCorrespondence[email protected]
https://orcid.org/0000-0002-8722-4108View further author information
https://orcid.org/0000-0002-8722-4108View further author information, , Mark S. Taylord Department of Clinical Immunology and Allergy, Westmead Hospital and Westmead Clinical School, University of Sydney, Sydney, NSW, Australiahttps://orcid.org/0000-0003-1270-7209View further author information
https://orcid.org/0000-0003-1270-7209View further author information, , Violaine Planté-Bordeneuvef Neurology – Amyloid Network, CHU Henri Mondor, APHP, University Paris Est – Créteil, Créteil, Francehttps://orcid.org/0000-0002-7880-2316View further author information
https://orcid.org/0000-0002-7880-2316View further author information, John L. Berkg Boston Medical Center, Boston University, Boston, Massachusetts, USAhttps://orcid.org/0000-0002-1768-2373View further author information
https://orcid.org/0000-0002-1768-2373View further author information, Alejandra González-Duarteh Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, D.F., Méxicohttps://orcid.org/0000-0002-2434-9560View further author information
https://orcid.org/0000-0002-2434-9560View further author information, Julian D. Gillmorei National Amyloidosis Centre, University College London, Royal Free Hospital, London, UKhttps://orcid.org/0000-0001-6174-9232View further author information
https://orcid.org/0000-0001-6174-9232View further author information, Soon-Chai Lowj Department of Medicine, Division of Neurology, University Malaya Medical Centre, Kuala Lumpur, Malaysiahttps://orcid.org/0000-0003-2392-6570View further author information
https://orcid.org/0000-0003-2392-6570View further author information, Yoshiki Sekijimak Department of Medicine (Neurology & Rheumatology), Shinshu University School of Medicine, Matsumoto, Japanhttps://orcid.org/0000-0002-8132-2743View further author information
https://orcid.org/0000-0002-8132-2743View further author information, Laura Obicil Amyloidosis Research and Treatment Centre, IRCCS Fondazione Policlinico San Matteo, Pavia, Italyhttps://orcid.org/0000-0001-7468-700XView further author information
https://orcid.org/0000-0001-7468-700XView further author information, , Prajakta Badrim Alnylam Pharmaceuticals, Cambridge, Massachusetts, USAhttps://orcid.org/0000-0003-1248-616XView further author information
https://orcid.org/0000-0003-1248-616XView further author information, , , Michael Polydefkisn Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USAhttps://orcid.org/0000-0002-7584-7447View further author information
https://orcid.org/0000-0002-7584-7447View further author information & The HELIOS-A Collaborators show all